These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17300723)

  • 1. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
    Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
    Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
    Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
    PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
    Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
    J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.
    Abbate I; Lo Iacono O; Di Stefano R; Cappiello G; Girardi E; Longo R; Ferraro D; Antonucci G; Di Marco V; Solmone M; Craxì A; Ippolito G; Capobianchi MR
    J Hepatol; 2004 May; 40(5):831-6. PubMed ID: 15094232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.
    Moreau I; Levis J; Crosbie O; Kenny-Walsh E; Fanning LJ
    Virol J; 2008 Jul; 5():78. PubMed ID: 18613968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
    Kurbanov F; Tanaka Y; Matsuura K; Sugauchi F; Elkady A; Khan A; Hasegawa I; Ohno T; Tokuda H; Mizokami M
    J Infect Dis; 2010 Jun; 201(11):1663-71. PubMed ID: 20420509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV.
    Abbate I; Cappiello G; Lo Iacono O; Longo R; Ferraro D; Antonucci G; Di Marco V; Di Stefano R; Craxì A; Solmone MC; Spanò A; Ippolito G; Capobianchi MR
    J Biol Regul Homeost Agents; 2003; 17(2):162-5. PubMed ID: 14518716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
    Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
    Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin.
    Salmerón J; Casado J; Rueda PM; Lafuente V; Diago M; Romero-Gómez M; Palacios A; León J; Gila A; Quiles R; Rodriguez L; Ruiz-Extremera A
    J Clin Virol; 2008 Apr; 41(4):264-9. PubMed ID: 18221912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.